Age-related macular degeneration (AMD) remains a leading cause of vision loss, but new therapies are reshaping its treatment.

The vision research community rallies to protect the National Eye Institute from funding cuts, emphasizing its vital role in preventing blindness and advancing treatments.

In early research, OCU410ST, a gene therapy for Stargardt disease, demonstrated slowed lesion growth by 48% at the 12-month follow-up in evaluable treated eyes.

This systematic review comprehensively summarizes treatment approaches for all types of age-related macular degeneration (AMD ...

The UC Davis Department of Ophthalmology has received a five-year, $3.6 million grant from the National Eye Institute to ...

Age-related macular degeneration (AMD) remains a leading cause of vision loss globally, with significant advancements in ...

Age-related macular degeneration (AMD) remains a leading cause of vision loss globally, with significant advancements in treatment options for both ...

Lawrence Sincich, Ph.D. Lawrence Sincich, Ph.D., professor at the University of Alabama at Birmingham School of Optometry was ...

A man living with the biggest cause of sight loss is calling on more people with a diagnosis of macular disease to seek vital ...

Our eyes are incredible tools, but like the rest of our bodies, they undergo changes as we age. Protecting your vision isn't ...

A new study examining age-related macular degeneration (AMD) among elderly residents in Egyptian geriatric homes revealed connections between this vision condition and dangerous falls.

Hugh Linehan shares his experience of macular degeneration – and the losses, large and small, that come with it ...